Thr1616

Site Information
ySsRtPGtPGtPsyP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 450181
Available spectra: 2 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 12 )
Disease tissue studied:	breast cancer ( 5 , 6 , 12 ) , breast ductal carcinoma ( 5 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 , 5 ) , lung cancer ( 9 , 12 ) , non-small cell lung cancer ( 9 , 12 ) , non-small cell lung adenocarcinoma ( 9 ) , non-small cell large cell lung carcinoma ( 9 ) , pancreatic ductal adenocarcinoma ( 7 ) , melanoma skin cancer ( 4 )
Relevant cell line - cell type - tissue:	'pancreatic, ductal'-pancreas ( 7 ) , breast ( 2 , 5 ) , BT-20 (breast cell) ( 12 ) , BT-549 (breast cell) ( 12 ) , Calu 6 (pulmonary) ( 12 ) , DMS79 (pulmonary) ( 8 ) , H2009 (pulmonary) ( 12 ) , H2077 (pulmonary) ( 12 ) , H2887 (pulmonary) ( 12 ) , H322M (pulmonary) ( 12 ) , HCC1359 (pulmonary) ( 12 ) , HCC1937 (breast cell) ( 12 ) , HCC2279 (pulmonary) ( 12 ) , HCC366 (pulmonary) ( 12 ) , HCC4006 (pulmonary) ( 12 ) , HCC78 (pulmonary) ( 9 , 12 ) , HeLa (cervical) ( 1 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 6 ) , HMLER ('stem, breast cancer') ( 6 ) , HOP62 (pulmonary) ( 12 ) , LOU-NH91 (squamous) ( 12 ) , lung ( 8 , 9 ) , MCF-7 (breast cell) ( 3 , 12 ) , MDA-MB-231 (breast cell) ( 12 ) , MDA-MB-468 (breast cell) ( 12 ) , NCI-H128 (pulmonary) ( 8 ) , NCI-H1395 (pulmonary) ( 12 ) , NCI-H1417 (pulmonary) ( 8 ) , NCI-H1568 (pulmonary) ( 12 ) , NCI-H1648 (pulmonary) ( 12 ) , NCI-H1781 (pulmonary) ( 9 ) , NCI-H2030 (pulmonary) ( 12 ) , NCI-H209 (pulmonary) ( 8 ) , NCI-H2172 (pulmonary) ( 12 ) , NCI-H2228 (pulmonary) ( 9 ) , NCI-H3122 (pulmonary) ( 9 ) , NCI-H322 (pulmonary) ( 12 ) , NCI-H460 (pulmonary) ( 12 ) , NCI-H524 (pulmonary) ( 8 ) , NCI-H647 (pulmonary) ( 12 ) , NCI-H661 (pulmonary) ( 9 ) , WM239A (melanocyte) ( 4 )

Upstream Regulation
Treatments:	metformin ( 3 )

References
1	Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296 27281782 Curated Info
2	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
3	Sacco F, et al. (2016) Deep Proteomics of Breast Cancer Cells Reveals that Metformin Rewires Signaling Networks Away from a Pro-growth State. Cell Syst 2, 159-71 27135362 Curated Info
4	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
5	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
6	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
7	Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948 24670416 Curated Info
8	Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
9	Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
10	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
11	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
12	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info